We have located links that may give you full text access.
English Abstract
Journal Article
[Effects of retinoid Ro 40-8757 on human cancer cell lines in vitro].
Ai Zheng = Aizheng = Chinese Journal of Cancer 2002 October
BACKGROUND & OBJECTIVES: The retinoids are potent anti-tumor drugs affecting cellular proliferation and inducing cell differetiation or apoptosis. This study was designed to investigate the anti-proliferative effect of a new-developed retinoid, Ro 40-8757, on cell structure, cell cycle and cell cycle proteins of four human cancer cell lines in vitro in order to reveal its probable mechanism.
METHODS: MTT assay was used to determine the anti-proliferative effects of Ro 40-8757 on human cancer cell lines CCL-187, CCL-229, JF-305, and ASPC-1. Microscopy was used to observe CCL-187 morphological changes. Flow cytometry was performed to investigate the influence of Ro 40-8757 on cell cycle. Western blot analysis was conducted to detect the cell cycle proteins p16, p21, and p27 as to discuss the possible mechanism.
RESULTS: Ro 40-8757 significantly inhibited the growth of the four cancer cell lines in a dose-, time-dependent manner and without any signs of cytotoxicity, differentiation, or apoptosis. After treating with Ro 40-8757, the cell of CCL-187 was arrested at G0/G1 phase. Both p21 and p27 were rapidly increasing at the first 12 hours after exposed to the agent, then decreasing slowly in the 24, 48 hours, and increasing again in 72 to 144 hours. P16 did not express at all either before or after agent treatment.
CONCLUSION: The results suggest that Ro 40-8757 inhibits the growth of human cancer cell lines in vitro by means of cell cycle arrest (mediated by up-regulating cell cycle protein P21 and P27) instead of cytotoxic effects, differentiation, or apoptosis.
METHODS: MTT assay was used to determine the anti-proliferative effects of Ro 40-8757 on human cancer cell lines CCL-187, CCL-229, JF-305, and ASPC-1. Microscopy was used to observe CCL-187 morphological changes. Flow cytometry was performed to investigate the influence of Ro 40-8757 on cell cycle. Western blot analysis was conducted to detect the cell cycle proteins p16, p21, and p27 as to discuss the possible mechanism.
RESULTS: Ro 40-8757 significantly inhibited the growth of the four cancer cell lines in a dose-, time-dependent manner and without any signs of cytotoxicity, differentiation, or apoptosis. After treating with Ro 40-8757, the cell of CCL-187 was arrested at G0/G1 phase. Both p21 and p27 were rapidly increasing at the first 12 hours after exposed to the agent, then decreasing slowly in the 24, 48 hours, and increasing again in 72 to 144 hours. P16 did not express at all either before or after agent treatment.
CONCLUSION: The results suggest that Ro 40-8757 inhibits the growth of human cancer cell lines in vitro by means of cell cycle arrest (mediated by up-regulating cell cycle protein P21 and P27) instead of cytotoxic effects, differentiation, or apoptosis.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app